This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oxytocin Administration in the Third Stage of Labour - A Study of Appropriate Route and Dose

This study has been completed.
Information provided by:
Memorial University of Newfoundland Identifier:
First received: September 12, 2005
Last updated: November 8, 2012
Last verified: November 2012
Mothers are given the medication oxytocin after birth to help the uterus (womb) contract and therefore reduce blood loss. In Canada, oxytocin is given either into the muscle of the thigh or into a vein. However, it is not known which route is better.This study will test which dose and route of oxytocin is best in reducing blood loss following vaginal delivery.

Condition Intervention Phase
Third Stage of Labour Drug: oxytocin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intramuscular Versus Intravascular Oxytocin for the Third Stage of Labour

Resource links provided by NLM:

Further study details as provided by Memorial University of Newfoundland:

Primary Outcome Measures:
  • change in hematocrit

Secondary Outcome Measures:
  • estimated blood loss
  • postpartum hemorrhage (estimated blood loss > 500cc)
  • severe postpartum hemorrhage (estimated blood loss > 1000cc)
  • incidence of hypotension
  • length of third stage of labour
  • need for blood transfusion
  • incidence of retained placenta
  • need for dilatation and curettage
  • need for hysterectomy
  • need for additional oxytocics after delivery
  • postpartum antibiotic use
  • maternal satisfaction
  • bleeding needing readmission

Enrollment: 300
Study Start Date: September 2005
Study Completion Date: July 2007
Arms Assigned Interventions
Active Comparator: group B
women in group B will receive 10 uts oxytocin IM
Drug: oxytocin
Active Comparator: group C
women in group C will receive oxytocin 5 uts IV
Drug: oxytocin
Active Comparator: group A
women in group A will receive oxytocin 5 uts IM
Drug: oxytocin


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women 19 years and older
  • singleton pregnancy
  • 32 weeks gestation
  • spontaneous vaginal delivery

Exclusion Criteria:

  • previous postpartum hemorrhage
  • placenta previa
  • grand multiparity (>4)
  • anticoagulation therapy
  • delivery prior to 32 weeks gestation
  • operative vaginal delivery
  • antepartum hemorrhage > 20 weeks
  • hemoglobin <10g/dL
  • multiple gestation
  • intrauterine death
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00200252

Canada, Newfoundland and Labrador
Women's Health Centre, Eastern Health
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Sponsors and Collaborators
Memorial University of Newfoundland
Principal Investigator: Colleen L Cook, MD Resident, Discipline Obstetrics and Gynecology, Memorial University of Newfoundland
Study Director: Joan Crane, MD Faculty, Discipline Obstetrics and Gynecolgy, Memorial University of Newfoundland
  More Information Identifier: NCT00200252     History of Changes
Other Study ID Numbers: HIC05.79
Study First Received: September 12, 2005
Last Updated: November 8, 2012

Keywords provided by Memorial University of Newfoundland:
third stage
blood loss

Additional relevant MeSH terms:
Reproductive Control Agents
Physiological Effects of Drugs processed this record on August 17, 2017